nodes	percent_of_prediction	percent_of_DWPC	metapath
Famotidine—SLC22A2—Cisplatin—esophageal cancer	0.338	0.642	CbGbCtD
Famotidine—SLC22A8—Methotrexate—esophageal cancer	0.188	0.358	CbGbCtD
Famotidine—HRH2—gastric juice—esophageal cancer	0.119	0.743	CbGeAlD
Famotidine—HRH2—Secretion of Hydrochloric Acid in Parietal Cells—ATP4A—esophageal cancer	0.0225	0.182	CbGpPWpGaD
Famotidine—Extravasation—Carboplatin—esophageal cancer	0.0101	0.0538	CcSEcCtD
Famotidine—HRH2—digestive system—esophageal cancer	0.00729	0.0453	CbGeAlD
Famotidine—SLC22A2—digestive system—esophageal cancer	0.00664	0.0413	CbGeAlD
Famotidine—HRH2—lung—esophageal cancer	0.00609	0.0379	CbGeAlD
Famotidine—SLC22A2—Neurotransmitter Clearance In The Synaptic Cleft—ALDH2—esophageal cancer	0.00563	0.0454	CbGpPWpGaD
Famotidine—SLC47A1—digestive system—esophageal cancer	0.00562	0.035	CbGeAlD
Famotidine—SLC22A2—Abacavir transmembrane transport—ABCB1—esophageal cancer	0.00512	0.0412	CbGpPWpGaD
Famotidine—SLC47A1—lung—esophageal cancer	0.0047	0.0292	CbGeAlD
Famotidine—HRH2—lymph node—esophageal cancer	0.00416	0.0259	CbGeAlD
Famotidine—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.00396	0.0319	CbGpPWpGaD
Famotidine—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00362	0.0292	CbGpPWpGaD
Famotidine—CYP2C19—digestive system—esophageal cancer	0.00362	0.0225	CbGeAlD
Famotidine—Sneezing—Capecitabine—esophageal cancer	0.00346	0.0183	CcSEcCtD
Famotidine—SLC47A1—lymph node—esophageal cancer	0.00321	0.02	CbGeAlD
Famotidine—Infection—Carboplatin—esophageal cancer	0.00314	0.0167	CcSEcCtD
Famotidine—Extravasation—Cisplatin—esophageal cancer	0.00297	0.0158	CcSEcCtD
Famotidine—Interstitial pneumonia—Methotrexate—esophageal cancer	0.00295	0.0156	CcSEcCtD
Famotidine—SLC22A2—Abacavir transport and metabolism—ABCB1—esophageal cancer	0.00294	0.0237	CbGpPWpGaD
Famotidine—Appetite absent—Methotrexate—esophageal cancer	0.00286	0.0152	CcSEcCtD
Famotidine—Bone marrow depression—Capecitabine—esophageal cancer	0.00283	0.015	CcSEcCtD
Famotidine—Pain—Carboplatin—esophageal cancer	0.0027	0.0143	CcSEcCtD
Famotidine—Wheezing—Cisplatin—esophageal cancer	0.00252	0.0134	CcSEcCtD
Famotidine—Body temperature increased—Carboplatin—esophageal cancer	0.0025	0.0132	CcSEcCtD
Famotidine—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.00239	0.0192	CbGpPWpGaD
Famotidine—CYP2C19—CYP2E1 reactions—CYP2A6—esophageal cancer	0.0023	0.0185	CbGpPWpGaD
Famotidine—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.00217	0.0175	CbGpPWpGaD
Famotidine—HRH2—G alpha (s) signalling events—ADCYAP1—esophageal cancer	0.00212	0.0171	CbGpPWpGaD
Famotidine—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.00212	0.0112	CcSEcCtD
Famotidine—Bone marrow depression—Methotrexate—esophageal cancer	0.00211	0.0112	CcSEcCtD
Famotidine—Nasal congestion—Cisplatin—esophageal cancer	0.00207	0.011	CcSEcCtD
Famotidine—Interstitial lung disease—Methotrexate—esophageal cancer	0.00201	0.0107	CcSEcCtD
Famotidine—Neck pain—Capecitabine—esophageal cancer	0.00194	0.0103	CcSEcCtD
Famotidine—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.00187	0.015	CbGpPWpGaD
Famotidine—Influenza like illness—Capecitabine—esophageal cancer	0.00186	0.00986	CcSEcCtD
Famotidine—Face oedema—Cisplatin—esophageal cancer	0.00182	0.00966	CcSEcCtD
Famotidine—Gingivitis—Methotrexate—esophageal cancer	0.00181	0.00963	CcSEcCtD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.0018	0.0145	CbGpPWpGaD
Famotidine—Irritability—Cisplatin—esophageal cancer	0.0018	0.00955	CcSEcCtD
Famotidine—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00171	0.0137	CbGpPWpGaD
Famotidine—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.0017	0.00901	CcSEcCtD
Famotidine—Cramp muscle—Cisplatin—esophageal cancer	0.0017	0.00901	CcSEcCtD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00165	0.0133	CbGpPWpGaD
Famotidine—Extravasation—Methotrexate—esophageal cancer	0.00163	0.00867	CcSEcCtD
Famotidine—Ear pain—Capecitabine—esophageal cancer	0.00163	0.00864	CcSEcCtD
Famotidine—Photosensitivity—Capecitabine—esophageal cancer	0.00158	0.0084	CcSEcCtD
Famotidine—Swelling—Capecitabine—esophageal cancer	0.00157	0.00836	CcSEcCtD
Famotidine—Abdominal discomfort—Cisplatin—esophageal cancer	0.00156	0.00829	CcSEcCtD
Famotidine—Pancytopenia—Cisplatin—esophageal cancer	0.00155	0.00821	CcSEcCtD
Famotidine—Libido decreased—Capecitabine—esophageal cancer	0.0015	0.00795	CcSEcCtD
Famotidine—CYP2C19—Xenobiotics—CYP2A6—esophageal cancer	0.00142	0.0115	CbGpPWpGaD
Famotidine—Pain in extremity—Capecitabine—esophageal cancer	0.00139	0.00737	CcSEcCtD
Famotidine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00138	0.00731	CcSEcCtD
Famotidine—CYP2C19—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00137	0.011	CbGpPWpGaD
Famotidine—Migraine—Capecitabine—esophageal cancer	0.00137	0.00726	CcSEcCtD
Famotidine—Face oedema—Capecitabine—esophageal cancer	0.00134	0.00712	CcSEcCtD
Famotidine—Bradycardia—Cisplatin—esophageal cancer	0.00133	0.00704	CcSEcCtD
Famotidine—Irritability—Capecitabine—esophageal cancer	0.00133	0.00704	CcSEcCtD
Famotidine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.0013	0.0105	CbGpPWpGaD
Famotidine—Gynaecomastia—Methotrexate—esophageal cancer	0.00127	0.00677	CcSEcCtD
Famotidine—Dry skin—Capecitabine—esophageal cancer	0.00127	0.00676	CcSEcCtD
Famotidine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00125	0.00664	CcSEcCtD
Famotidine—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00125	0.00664	CcSEcCtD
Famotidine—HRH2—G alpha (s) signalling events—PDE4D—esophageal cancer	0.00125	0.0101	CbGpPWpGaD
Famotidine—CYP2C19—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00122	0.00985	CbGpPWpGaD
Famotidine—Tinnitus—Cisplatin—esophageal cancer	0.00122	0.00645	CcSEcCtD
Famotidine—Flushing—Cisplatin—esophageal cancer	0.00121	0.00642	CcSEcCtD
Famotidine—Influenza—Capecitabine—esophageal cancer	0.0012	0.00637	CcSEcCtD
Famotidine—HRH2—G alpha (s) signalling events—GNG7—esophageal cancer	0.00119	0.00957	CbGpPWpGaD
Famotidine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00119	0.00957	CbGpPWpGaD
Famotidine—Bronchospasm—Capecitabine—esophageal cancer	0.00118	0.00627	CcSEcCtD
Famotidine—Photosensitivity—Methotrexate—esophageal cancer	0.00118	0.00625	CcSEcCtD
Famotidine—Arrhythmia—Cisplatin—esophageal cancer	0.00116	0.00618	CcSEcCtD
Famotidine—Bronchitis—Capecitabine—esophageal cancer	0.00115	0.00613	CcSEcCtD
Famotidine—Alopecia—Cisplatin—esophageal cancer	0.00115	0.00611	CcSEcCtD
Famotidine—Abdominal discomfort—Capecitabine—esophageal cancer	0.00115	0.00611	CcSEcCtD
Famotidine—Pancytopenia—Capecitabine—esophageal cancer	0.00114	0.00605	CcSEcCtD
Famotidine—Neutropenia—Capecitabine—esophageal cancer	0.00112	0.00596	CcSEcCtD
Famotidine—Dysuria—Capecitabine—esophageal cancer	0.00112	0.00596	CcSEcCtD
Famotidine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00112	0.00592	CcSEcCtD
Famotidine—CYP2C19—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.0011	0.00889	CbGpPWpGaD
Famotidine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.0011	0.00582	CcSEcCtD
Famotidine—Muscle spasms—Cisplatin—esophageal cancer	0.00109	0.00579	CcSEcCtD
Famotidine—Depression—Capecitabine—esophageal cancer	0.00107	0.00567	CcSEcCtD
Famotidine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00106	0.00563	CcSEcCtD
Famotidine—Anaemia—Cisplatin—esophageal cancer	0.00105	0.00557	CcSEcCtD
Famotidine—Jaundice—Capecitabine—esophageal cancer	0.00104	0.00554	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00103	0.00827	CbGpPWpGaD
Famotidine—Haematuria—Capecitabine—esophageal cancer	0.00102	0.00542	CcSEcCtD
Famotidine—Leukopenia—Cisplatin—esophageal cancer	0.00102	0.00539	CcSEcCtD
Famotidine—Agranulocytosis—Capecitabine—esophageal cancer	0.000999	0.0053	CcSEcCtD
Famotidine—Irritability—Methotrexate—esophageal cancer	0.000987	0.00524	CcSEcCtD
Famotidine—Convulsion—Cisplatin—esophageal cancer	0.000983	0.00522	CcSEcCtD
Famotidine—Bradycardia—Capecitabine—esophageal cancer	0.000978	0.00519	CcSEcCtD
Famotidine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000978	0.00788	CbGpPWpGaD
Famotidine—Myalgia—Cisplatin—esophageal cancer	0.000966	0.00513	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000964	0.00777	CbGpPWpGaD
Famotidine—Anxiety—Cisplatin—esophageal cancer	0.000963	0.00511	CcSEcCtD
Famotidine—Hepatitis—Capecitabine—esophageal cancer	0.000961	0.0051	CcSEcCtD
Famotidine—Pharyngitis—Capecitabine—esophageal cancer	0.000953	0.00506	CcSEcCtD
Famotidine—CYP2C19—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.000936	0.00754	CbGpPWpGaD
Famotidine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000931	0.00494	CcSEcCtD
Famotidine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000926	0.00492	CcSEcCtD
Famotidine—Oedema—Cisplatin—esophageal cancer	0.000926	0.00492	CcSEcCtD
Famotidine—Infection—Cisplatin—esophageal cancer	0.00092	0.00488	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000914	0.00737	CbGpPWpGaD
Famotidine—Erythema multiforme—Capecitabine—esophageal cancer	0.000908	0.00482	CcSEcCtD
Famotidine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000907	0.00481	CcSEcCtD
Famotidine—Tinnitus—Capecitabine—esophageal cancer	0.000896	0.00476	CcSEcCtD
Famotidine—Flushing—Capecitabine—esophageal cancer	0.000892	0.00473	CcSEcCtD
Famotidine—Anorexia—Cisplatin—esophageal cancer	0.000883	0.00469	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000872	0.00703	CbGpPWpGaD
Famotidine—Arrhythmia—Capecitabine—esophageal cancer	0.000858	0.00456	CcSEcCtD
Famotidine—Abdominal discomfort—Methotrexate—esophageal cancer	0.000857	0.00455	CcSEcCtD
Famotidine—CYP2C19—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.000853	0.00687	CbGpPWpGaD
Famotidine—Alopecia—Capecitabine—esophageal cancer	0.000849	0.00451	CcSEcCtD
Famotidine—Pancytopenia—Methotrexate—esophageal cancer	0.000849	0.00451	CcSEcCtD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.000848	0.00683	CbGpPWpGaD
Famotidine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000844	0.00448	CcSEcCtD
Famotidine—Mental disorder—Capecitabine—esophageal cancer	0.000842	0.00447	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000836	0.00674	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000836	0.00674	CbGpPWpGaD
Famotidine—Dysuria—Methotrexate—esophageal cancer	0.000835	0.00444	CcSEcCtD
Famotidine—Neutropenia—Methotrexate—esophageal cancer	0.000835	0.00444	CcSEcCtD
Famotidine—Paraesthesia—Cisplatin—esophageal cancer	0.000831	0.00441	CcSEcCtD
Famotidine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00083	0.00441	CcSEcCtD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00083	0.00669	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000825	0.00665	CbGpPWpGaD
Famotidine—Erectile dysfunction—Methotrexate—esophageal cancer	0.000823	0.00437	CcSEcCtD
Famotidine—Dysgeusia—Capecitabine—esophageal cancer	0.000819	0.00435	CcSEcCtD
Famotidine—CYP2C19—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000819	0.0066	CbGpPWpGaD
Famotidine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000816	0.00433	CcSEcCtD
Famotidine—Back pain—Capecitabine—esophageal cancer	0.000809	0.0043	CcSEcCtD
Famotidine—Decreased appetite—Cisplatin—esophageal cancer	0.000805	0.00427	CcSEcCtD
Famotidine—Muscle spasms—Capecitabine—esophageal cancer	0.000804	0.00427	CcSEcCtD
Famotidine—Depression—Methotrexate—esophageal cancer	0.000794	0.00422	CcSEcCtD
Famotidine—Pain—Cisplatin—esophageal cancer	0.000792	0.0042	CcSEcCtD
Famotidine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00079	0.00419	CcSEcCtD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.000775	0.00625	CbGpPWpGaD
Famotidine—Anaemia—Capecitabine—esophageal cancer	0.000773	0.0041	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—ADCYAP1—esophageal cancer	0.000769	0.0062	CbGpPWpGaD
Famotidine—Feeling abnormal—Cisplatin—esophageal cancer	0.000763	0.00405	CcSEcCtD
Famotidine—Haematuria—Methotrexate—esophageal cancer	0.00076	0.00403	CcSEcCtD
Famotidine—Syncope—Capecitabine—esophageal cancer	0.00075	0.00398	CcSEcCtD
Famotidine—Leukopenia—Capecitabine—esophageal cancer	0.000749	0.00397	CcSEcCtD
Famotidine—Agranulocytosis—Methotrexate—esophageal cancer	0.000743	0.00395	CcSEcCtD
Famotidine—Palpitations—Capecitabine—esophageal cancer	0.000739	0.00392	CcSEcCtD
Famotidine—Loss of consciousness—Capecitabine—esophageal cancer	0.000735	0.0039	CcSEcCtD
Famotidine—Body temperature increased—Cisplatin—esophageal cancer	0.000732	0.00389	CcSEcCtD
Famotidine—Cough—Capecitabine—esophageal cancer	0.00073	0.00387	CcSEcCtD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000724	0.00583	CbGpPWpGaD
Famotidine—Hepatitis—Methotrexate—esophageal cancer	0.000715	0.0038	CcSEcCtD
Famotidine—Arthralgia—Capecitabine—esophageal cancer	0.000712	0.00378	CcSEcCtD
Famotidine—Chest pain—Capecitabine—esophageal cancer	0.000712	0.00378	CcSEcCtD
Famotidine—Myalgia—Capecitabine—esophageal cancer	0.000712	0.00378	CcSEcCtD
Famotidine—Pharyngitis—Methotrexate—esophageal cancer	0.00071	0.00377	CcSEcCtD
Famotidine—Anxiety—Capecitabine—esophageal cancer	0.00071	0.00377	CcSEcCtD
Famotidine—Dry mouth—Capecitabine—esophageal cancer	0.000696	0.0037	CcSEcCtD
Famotidine—Confusional state—Capecitabine—esophageal cancer	0.000688	0.00365	CcSEcCtD
Famotidine—Oedema—Capecitabine—esophageal cancer	0.000683	0.00362	CcSEcCtD
Famotidine—Hypersensitivity—Cisplatin—esophageal cancer	0.000682	0.00362	CcSEcCtD
Famotidine—Infection—Capecitabine—esophageal cancer	0.000678	0.0036	CcSEcCtD
Famotidine—Erythema multiforme—Methotrexate—esophageal cancer	0.000676	0.00359	CcSEcCtD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000673	0.00542	CbGpPWpGaD
Famotidine—Shock—Capecitabine—esophageal cancer	0.000671	0.00357	CcSEcCtD
Famotidine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000668	0.00355	CcSEcCtD
Famotidine—Tinnitus—Methotrexate—esophageal cancer	0.000667	0.00354	CcSEcCtD
Famotidine—Asthenia—Cisplatin—esophageal cancer	0.000664	0.00353	CcSEcCtD
Famotidine—Anorexia—Capecitabine—esophageal cancer	0.000651	0.00345	CcSEcCtD
Famotidine—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000649	0.00523	CbGpPWpGaD
Famotidine—CYP2C19—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000649	0.00523	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000634	0.00511	CbGpPWpGaD
Famotidine—Diarrhoea—Cisplatin—esophageal cancer	0.000634	0.00336	CcSEcCtD
Famotidine—Alopecia—Methotrexate—esophageal cancer	0.000632	0.00336	CcSEcCtD
Famotidine—Mental disorder—Methotrexate—esophageal cancer	0.000627	0.00333	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000622	0.0033	CcSEcCtD
Famotidine—Insomnia—Capecitabine—esophageal cancer	0.000617	0.00328	CcSEcCtD
Famotidine—Paraesthesia—Capecitabine—esophageal cancer	0.000613	0.00325	CcSEcCtD
Famotidine—Dysgeusia—Methotrexate—esophageal cancer	0.00061	0.00324	CcSEcCtD
Famotidine—Back pain—Methotrexate—esophageal cancer	0.000602	0.0032	CcSEcCtD
Famotidine—Dyspepsia—Capecitabine—esophageal cancer	0.000601	0.00319	CcSEcCtD
Famotidine—Decreased appetite—Capecitabine—esophageal cancer	0.000593	0.00315	CcSEcCtD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000591	0.00476	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00059	0.00475	CbGpPWpGaD
Famotidine—Vomiting—Cisplatin—esophageal cancer	0.000589	0.00313	CcSEcCtD
Famotidine—Fatigue—Capecitabine—esophageal cancer	0.000588	0.00312	CcSEcCtD
Famotidine—Rash—Cisplatin—esophageal cancer	0.000584	0.0031	CcSEcCtD
Famotidine—Constipation—Capecitabine—esophageal cancer	0.000584	0.0031	CcSEcCtD
Famotidine—Pain—Capecitabine—esophageal cancer	0.000584	0.0031	CcSEcCtD
Famotidine—CYP2C19—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000583	0.0047	CbGpPWpGaD
Famotidine—Dermatitis—Cisplatin—esophageal cancer	0.000583	0.0031	CcSEcCtD
Famotidine—Anaemia—Methotrexate—esophageal cancer	0.000575	0.00306	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000575	0.00463	CbGpPWpGaD
Famotidine—Feeling abnormal—Capecitabine—esophageal cancer	0.000562	0.00299	CcSEcCtD
Famotidine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000558	0.00296	CcSEcCtD
Famotidine—Leukopenia—Methotrexate—esophageal cancer	0.000557	0.00296	CcSEcCtD
Famotidine—CYP2C19—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000551	0.00444	CbGpPWpGaD
Famotidine—Nausea—Cisplatin—esophageal cancer	0.00055	0.00292	CcSEcCtD
Famotidine—Cough—Methotrexate—esophageal cancer	0.000543	0.00288	CcSEcCtD
Famotidine—Urticaria—Capecitabine—esophageal cancer	0.000542	0.00288	CcSEcCtD
Famotidine—Body temperature increased—Capecitabine—esophageal cancer	0.00054	0.00286	CcSEcCtD
Famotidine—Abdominal pain—Capecitabine—esophageal cancer	0.00054	0.00286	CcSEcCtD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.000539	0.00435	CbGpPWpGaD
Famotidine—Convulsion—Methotrexate—esophageal cancer	0.000539	0.00286	CcSEcCtD
Famotidine—Myalgia—Methotrexate—esophageal cancer	0.00053	0.00281	CcSEcCtD
Famotidine—Arthralgia—Methotrexate—esophageal cancer	0.00053	0.00281	CcSEcCtD
Famotidine—Chest pain—Methotrexate—esophageal cancer	0.00053	0.00281	CcSEcCtD
Famotidine—Confusional state—Methotrexate—esophageal cancer	0.000512	0.00272	CcSEcCtD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00051	0.00411	CbGpPWpGaD
Famotidine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000508	0.0027	CcSEcCtD
Famotidine—Infection—Methotrexate—esophageal cancer	0.000505	0.00268	CcSEcCtD
Famotidine—Hypersensitivity—Capecitabine—esophageal cancer	0.000503	0.00267	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000499	0.00402	CbGpPWpGaD
Famotidine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000497	0.00264	CcSEcCtD
Famotidine—Asthenia—Capecitabine—esophageal cancer	0.00049	0.0026	CcSEcCtD
Famotidine—Anorexia—Methotrexate—esophageal cancer	0.000484	0.00257	CcSEcCtD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000483	0.00389	CbGpPWpGaD
Famotidine—Pruritus—Capecitabine—esophageal cancer	0.000483	0.00256	CcSEcCtD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000479	0.00386	CbGpPWpGaD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000477	0.00384	CbGpPWpGaD
Famotidine—CYP2C19—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00047	0.00379	CbGpPWpGaD
Famotidine—Diarrhoea—Capecitabine—esophageal cancer	0.000467	0.00248	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000464	0.00374	CbGpPWpGaD
Famotidine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000463	0.00246	CcSEcCtD
Famotidine—Insomnia—Methotrexate—esophageal cancer	0.00046	0.00244	CcSEcCtD
Famotidine—SLC22A2—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.000458	0.00369	CbGpPWpGaD
Famotidine—Paraesthesia—Methotrexate—esophageal cancer	0.000456	0.00242	CcSEcCtD
Famotidine—SLC22A8—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000454	0.00366	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000454	0.00366	CbGpPWpGaD
Famotidine—Somnolence—Methotrexate—esophageal cancer	0.000452	0.0024	CcSEcCtD
Famotidine—Dizziness—Capecitabine—esophageal cancer	0.000451	0.0024	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000451	0.00364	CbGpPWpGaD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000448	0.00361	CbGpPWpGaD
Famotidine—Dyspepsia—Methotrexate—esophageal cancer	0.000447	0.00237	CcSEcCtD
Famotidine—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000442	0.00356	CbGpPWpGaD
Famotidine—Decreased appetite—Methotrexate—esophageal cancer	0.000442	0.00235	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00044	0.00354	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—ADH7—esophageal cancer	0.000438	0.00353	CbGpPWpGaD
Famotidine—Fatigue—Methotrexate—esophageal cancer	0.000438	0.00233	CcSEcCtD
Famotidine—HRH2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000435	0.0035	CbGpPWpGaD
Famotidine—Pain—Methotrexate—esophageal cancer	0.000434	0.00231	CcSEcCtD
Famotidine—Vomiting—Capecitabine—esophageal cancer	0.000434	0.0023	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—GNG7—esophageal cancer	0.000431	0.00347	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000431	0.00347	CbGpPWpGaD
Famotidine—Rash—Capecitabine—esophageal cancer	0.00043	0.00228	CcSEcCtD
Famotidine—Dermatitis—Capecitabine—esophageal cancer	0.00043	0.00228	CcSEcCtD
Famotidine—SLC22A2—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000429	0.00346	CbGpPWpGaD
Famotidine—Headache—Capecitabine—esophageal cancer	0.000428	0.00227	CcSEcCtD
Famotidine—Feeling abnormal—Methotrexate—esophageal cancer	0.000419	0.00222	CcSEcCtD
Famotidine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000415	0.00221	CcSEcCtD
Famotidine—SLC22A8—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000411	0.00331	CbGpPWpGaD
Famotidine—Nausea—Capecitabine—esophageal cancer	0.000405	0.00215	CcSEcCtD
Famotidine—Urticaria—Methotrexate—esophageal cancer	0.000404	0.00214	CcSEcCtD
Famotidine—Body temperature increased—Methotrexate—esophageal cancer	0.000402	0.00213	CcSEcCtD
Famotidine—Abdominal pain—Methotrexate—esophageal cancer	0.000402	0.00213	CcSEcCtD
Famotidine—HRH2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000395	0.00318	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000394	0.00317	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000394	0.00317	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000386	0.00311	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—ADH1B—esophageal cancer	0.000384	0.0031	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CXCL2—esophageal cancer	0.00038	0.00306	CbGpPWpGaD
Famotidine—Hypersensitivity—Methotrexate—esophageal cancer	0.000374	0.00199	CcSEcCtD
Famotidine—Asthenia—Methotrexate—esophageal cancer	0.000365	0.00194	CcSEcCtD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000363	0.00293	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GDI2—esophageal cancer	0.000362	0.00292	CbGpPWpGaD
Famotidine—Pruritus—Methotrexate—esophageal cancer	0.000359	0.00191	CcSEcCtD
Famotidine—CYP2C19—Biological oxidations—CYP26A1—esophageal cancer	0.000357	0.00288	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—ANXA1—esophageal cancer	0.000353	0.00285	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000352	0.00284	CbGpPWpGaD
Famotidine—SLC22A2—Neuronal System—GNG7—esophageal cancer	0.000351	0.00283	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.00035	0.00282	CbGpPWpGaD
Famotidine—Diarrhoea—Methotrexate—esophageal cancer	0.000348	0.00185	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—SST—esophageal cancer	0.000344	0.00277	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000336	0.00271	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000336	0.00271	CbGpPWpGaD
Famotidine—Dizziness—Methotrexate—esophageal cancer	0.000336	0.00178	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—GHRL—esophageal cancer	0.000335	0.0027	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—GSTO1—esophageal cancer	0.000332	0.00268	CbGpPWpGaD
Famotidine—SLC22A2—Neuronal System—ALDH2—esophageal cancer	0.000329	0.00265	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—GSTO1—esophageal cancer	0.000328	0.00264	CbGpPWpGaD
Famotidine—Vomiting—Methotrexate—esophageal cancer	0.000323	0.00172	CcSEcCtD
Famotidine—Rash—Methotrexate—esophageal cancer	0.00032	0.0017	CcSEcCtD
Famotidine—Dermatitis—Methotrexate—esophageal cancer	0.00032	0.0017	CcSEcCtD
Famotidine—Headache—Methotrexate—esophageal cancer	0.000318	0.00169	CcSEcCtD
Famotidine—SLC22A2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000316	0.00255	CbGpPWpGaD
Famotidine—Nausea—Methotrexate—esophageal cancer	0.000302	0.0016	CcSEcCtD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.0003	0.00242	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000299	0.00241	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000286	0.0023	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—AKAP13—esophageal cancer	0.00028	0.00226	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000274	0.00221	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000274	0.00221	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000271	0.00218	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—ALDH2—esophageal cancer	0.000271	0.00218	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—KMT2D—esophageal cancer	0.000262	0.00211	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—GSTT1—esophageal cancer	0.000258	0.00208	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PDE4D—esophageal cancer	0.000256	0.00206	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—CYP2A6—esophageal cancer	0.000255	0.00205	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—AKAP13—esophageal cancer	0.000254	0.00205	CbGpPWpGaD
Famotidine—CYP2C19—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000249	0.002	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—GNG7—esophageal cancer	0.000244	0.00196	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—PTGS1—esophageal cancer	0.000241	0.00194	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ADCYAP1—esophageal cancer	0.000233	0.00188	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PDE4D—esophageal cancer	0.000233	0.00187	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000225	0.00181	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—GNG7—esophageal cancer	0.000221	0.00178	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CXCL2—esophageal cancer	0.000215	0.00173	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—WWOX—esophageal cancer	0.000213	0.00172	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000208	0.00167	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—CYP1B1—esophageal cancer	0.000205	0.00165	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FKBP1A—esophageal cancer	0.000203	0.00163	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000202	0.00163	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—ANXA1—esophageal cancer	0.0002	0.00161	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—WIF1—esophageal cancer	0.000198	0.0016	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000198	0.0016	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CXCL2—esophageal cancer	0.000195	0.00157	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—SST—esophageal cancer	0.000194	0.00156	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—CYP19A1—esophageal cancer	0.000193	0.00155	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00019	0.00153	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—GHRL—esophageal cancer	0.000189	0.00152	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000189	0.00152	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SLC52A3—esophageal cancer	0.000185	0.00149	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—BLVRB—esophageal cancer	0.000185	0.00149	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000183	0.00147	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—ANXA1—esophageal cancer	0.000181	0.00146	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—SST—esophageal cancer	0.000176	0.00142	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—GHRL—esophageal cancer	0.000172	0.00138	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PFN1—esophageal cancer	0.000171	0.00138	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000165	0.00133	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000158	0.00128	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CA1—esophageal cancer	0.000158	0.00127	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SLC10A2—esophageal cancer	0.000158	0.00127	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ELMO1—esophageal cancer	0.000154	0.00124	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—AKAP13—esophageal cancer	0.00015	0.00121	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CA2—esophageal cancer	0.000144	0.00116	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000139	0.00112	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PDE4D—esophageal cancer	0.000137	0.00111	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ADH7—esophageal cancer	0.000134	0.00108	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PLCE1—esophageal cancer	0.000134	0.00108	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000134	0.00108	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GNG7—esophageal cancer	0.000131	0.00105	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—XIAP—esophageal cancer	0.000122	0.000987	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ADH1B—esophageal cancer	0.000117	0.000946	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000117	0.00094	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CTNNA1—esophageal cancer	0.000116	0.000933	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CXCL2—esophageal cancer	0.000115	0.000928	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000115	0.000926	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—TYMP—esophageal cancer	0.000112	0.000904	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00011	0.000888	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP26A1—esophageal cancer	0.000109	0.00088	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PSME2—esophageal cancer	0.000108	0.000867	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PSME1—esophageal cancer	0.000108	0.000867	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ANXA1—esophageal cancer	0.000107	0.000863	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ALOX15—esophageal cancer	0.000106	0.000857	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000106	0.000853	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SST—esophageal cancer	0.000104	0.000839	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—BLVRB—esophageal cancer	0.000104	0.000835	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SLC52A3—esophageal cancer	0.000104	0.000835	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GHRL—esophageal cancer	0.000101	0.000818	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NOTCH3—esophageal cancer	0.000101	0.000818	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTO1—esophageal cancer	0.000101	0.000818	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—TPI1—esophageal cancer	0.000101	0.000818	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FBXW7—esophageal cancer	9.99e-05	0.000805	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ALDOB—esophageal cancer	9.73e-05	0.000784	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GAPDH—esophageal cancer	9.37e-05	0.000755	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CRABP1—esophageal cancer	9.28e-05	0.000748	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	9.27e-05	0.000747	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NOTCH2—esophageal cancer	9.1e-05	0.000734	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GNG7—esophageal cancer	8.83e-05	0.000711	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SLC10A2—esophageal cancer	8.82e-05	0.00071	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CA1—esophageal cancer	8.82e-05	0.00071	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ALDH2—esophageal cancer	8.27e-05	0.000667	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TGFBR2—esophageal cancer	8.08e-05	0.000651	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CA2—esophageal cancer	8.06e-05	0.00065	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	7.88e-05	0.000635	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTT1—esophageal cancer	7.87e-05	0.000634	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP2A6—esophageal cancer	7.78e-05	0.000627	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SMAD4—esophageal cancer	7.64e-05	0.000616	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ADH7—esophageal cancer	7.5e-05	0.000604	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PLCE1—esophageal cancer	7.5e-05	0.000604	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	7.41e-05	0.000597	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PTGS1—esophageal cancer	7.37e-05	0.000594	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ENO1—esophageal cancer	7.37e-05	0.000594	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	7.37e-05	0.000594	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PSME2—esophageal cancer	7.27e-05	0.000586	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PSME1—esophageal cancer	7.27e-05	0.000586	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ADH1B—esophageal cancer	6.57e-05	0.00053	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TYMP—esophageal cancer	6.28e-05	0.000506	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP1B1—esophageal cancer	6.27e-05	0.000505	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HIF1A—esophageal cancer	6.25e-05	0.000504	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP26A1—esophageal cancer	6.11e-05	0.000492	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—KDR—esophageal cancer	5.98e-05	0.000482	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ALOX15—esophageal cancer	5.95e-05	0.00048	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP19A1—esophageal cancer	5.9e-05	0.000475	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTO1—esophageal cancer	5.68e-05	0.000458	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TPI1—esophageal cancer	5.68e-05	0.000458	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NOTCH1—esophageal cancer	5.63e-05	0.000454	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ALDOB—esophageal cancer	5.45e-05	0.000439	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—HMOX1—esophageal cancer	5.38e-05	0.000434	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GAPDH—esophageal cancer	5.24e-05	0.000422	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CRABP1—esophageal cancer	5.2e-05	0.000419	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ABCB1—esophageal cancer	5.16e-05	0.000416	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CREBBP—esophageal cancer	5.11e-05	0.000412	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—EGFR—esophageal cancer	5.02e-05	0.000405	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GNG7—esophageal cancer	4.94e-05	0.000398	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CA—esophageal cancer	4.8e-05	0.000387	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ALDH2—esophageal cancer	4.63e-05	0.000373	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NOS3—esophageal cancer	4.57e-05	0.000369	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTT1—esophageal cancer	4.4e-05	0.000355	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CA—esophageal cancer	4.36e-05	0.000351	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP2A6—esophageal cancer	4.35e-05	0.000351	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	4.34e-05	0.00035	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ERBB2—esophageal cancer	4.28e-05	0.000345	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ENO1—esophageal cancer	4.13e-05	0.000333	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PTGS1—esophageal cancer	4.13e-05	0.000333	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PSME1—esophageal cancer	4.07e-05	0.000328	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PSME2—esophageal cancer	4.07e-05	0.000328	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCND1—esophageal cancer	3.78e-05	0.000305	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CDKN1A—esophageal cancer	3.66e-05	0.000295	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.55e-05	0.000286	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP1B1—esophageal cancer	3.51e-05	0.000283	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—EP300—esophageal cancer	3.48e-05	0.00028	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CREBBP—esophageal cancer	3.45e-05	0.000278	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP19A1—esophageal cancer	3.3e-05	0.000266	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NOS3—esophageal cancer	3.09e-05	0.000249	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MYC—esophageal cancer	3.03e-05	0.000244	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HMOX1—esophageal cancer	3.01e-05	0.000243	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—EGFR—esophageal cancer	2.97e-05	0.000239	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.95e-05	0.000238	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ABCB1—esophageal cancer	2.89e-05	0.000233	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PTGS2—esophageal cancer	2.83e-05	0.000228	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CA—esophageal cancer	2.57e-05	0.000207	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TP53—esophageal cancer	2.49e-05	0.000201	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—EP300—esophageal cancer	2.35e-05	0.000189	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.19e-05	0.000176	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CREBBP—esophageal cancer	1.93e-05	0.000156	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CA—esophageal cancer	1.74e-05	0.00014	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NOS3—esophageal cancer	1.73e-05	0.000139	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.58e-05	0.000127	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—EP300—esophageal cancer	1.32e-05	0.000106	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CA—esophageal cancer	9.73e-06	7.84e-05	CbGpPWpGaD
